Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuroimaging of Sedation With Remimazolam
NCT07290205Phase 1Recruiting
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of remimazolam in sedation. Primary endpoints: Explicit memory performance and Subjective pain ratings at Day 1. Started Mar 2026; status: recruiting.
02
Drugs
remimazolam
03
Conditions
sedation
Beyond the preview
Go deeper on NCT07290205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07290205.